Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, maximal use study to evaluate whether luliconazole in plasma acts as
an inhibitor of cytochrome P2C19 (CYP2C19) as measured by circulating levels of omeprazole
before and after treatment with a maximum dose of luliconazole cream 1% in participants with
moderate to severe tinea pedis and tinea cruris.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.